Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Solicitation (Request for quotation) from Defense Health Agency. Responses are due Nov 30, 2026 (10 days left).

Open to all (no set-aside)Any registered business can bid, large or small.Who qualifies
  • 10Days left to respond
  • 20 daysThis buyer usually gives
  • 12%Notices this buyer changes
  • -Typical award from this office

What BidCamel found about this buyer

  • This office usually gives bidders 20 days to respond; this notice gives 18 days.
  • It changed 12% of its 17 notices after posting, so check for amendments before you submit.
  • It has 1 open bids right now. See them all.
  • We have no past awards from this office yet.
Key details
Solicitation number
HT9402-27-Q-9102
NAICS code
325412 Pharmaceutical Preparation Manufacturing
Size standard for this code
1,300 employees
Set-aside
Open to all (no set-aside)
Buying
Product
Place
San Antonio, TX · Texas bids
Posted
Nov 12, 2026
Last changed
Nov 12, 2026
Contact
Contact details are on the SAM.gov notice. Open on SAM.gov

Description

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 newly approved drugs will be reviewed: Atebrioz – Skeletal Muscle Relaxants and Combinations – Subclass: NA Emcitate – Thyroid and Antithyroid Agents – Subclass: NA Hibsago – Hepatitis B Agents – Subclass: NA Juvmo – Parkinsons Agents – Subclass: NA Zegfrovy – Lung Cancer – Subclass: EGFR+ NSCLC The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9102. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.

Read the full notice and attachments on SAM.gov

Similar open bids

All open bids for NAICS 325412

From SAM.gov and USAspending.gov public data. BidCamel adds the buyer and award facts.

Save and get alerts